ONCIN Oncoinvent ASA

7.550USD73.00 NOK · OSL+2.53%Mkt Cap: 46.27M USDP/E: —

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body…

Key Statistics

Company
Market Cap46.27M USD
Enterprise Value22.98M USD
Revenue (TTM)2.51M USD
Gross Profit2.51M USD
Net Income (TTM)-16.04M USD
Revenue/Share0.84 USD
Last Price7.550 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees42
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0013711713
Valuation
P/E (Trailing)—
P/E (Forward)-2.57
PEG—
EV/EBITDA-1.33
EV/Revenue9.14
P/S18.40
P/B4.05
EPS (TTM)-8.61 USD
EPS (Forward)-2.94 USD
52W Range
4.14732% of range14.89
52W High14.89 USD
52W Low4.147 USD
Profitability
Gross Margin100.00%
Oper. Margin-721.06%
EBITDA Margin0.00%
Profit Margin-673.13%
ROE-105.98%
ROA-75.66%
ROIC—
ROCE-92.99%
Growth
Revenue Growth-31.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.43M USD
CapEx (TTM)12.31K USD
FCF Margin-336.91%
FCF Yield-18.31%
Net Debt-10.83M USD
Net Debt/EBITDA0.63
Net Debt/FCF—
Balance Sheet
Debt/Equity0.02
Current Ratio2.43
Quick Ratio2.43
Book Value/Sh1.86 USD
Cash/Share2.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJan 19, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.48 USD
Upside (mean)+52.1%
Target Range11.38 USD – 11.58 USD
11.38+52.1% to mean11.58
# Analysts2
Ownership
Shares Out.6.13M
Float2.85M
Insiders22.38%
Institutions35.27%
Technical
SMA 508.478 (-10.9%)
SMA 2006.617 (+14.1%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)15.94K
Avg Vol (10d)13.54K
Technical Indicators
RSI (14)54.6
MACD-1.3661
MACD Signal-2.9190
MACD Hist.+1.5530
BB Upper7.588 USD
BB Middle7.028 USD
BB Lower6.468 USD
BB Width15.93%
ATR (14)0.4566 USD
Vol Ratio (20d)1.02x

About Oncoinvent (OSL: ONCIN)

›

Oncoinvent (OSL: ONCIN) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 42 employees.

The shares were at 73.00 NOK on 19 November 2026, up 14.1% over 52 weeks. Its 52-week range is 40.10 NOK to 144.00 NOK: the price is 49.3% below the high and 82.0% above the low.

Its market capitalisation is 447.37M NOK.

Oncoinvent reports return on equity of -106.0% and revenue down 31.4% year over year.

It holds more cash than debt, a net cash position of 104.74M NOK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 111.00 NOK is 52.1% above the current price. The next earnings report is expected on 25 February 2027.